Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc, Univ KingstonfiledCriticalPentech Pharmaceuticals Inc
Priority claimed from PCT/US1995/004897external-prioritypatent/WO1995028930A1/en
Publication of MX9604981ApublicationCriticalpatent/MX9604981A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicinal Preparation
(AREA)
Abstract
Pyschogenic impotence or erectile dysfunction can be identified in psychogenic male patients and can be ameliorated, without substantial undesirable side effects, by sublingual administration of apomorphine dosage forms that contain about 2.5 to about 10 milligrams of apomorphine and dissolve within a time period of about 2 to about 5 minutes.
MX9604981A1995-04-211995-04-21Dosage forms and method for ameliorating male erectile dysfunction.
MX9604981A
(en)